Should I Buy G? G 2026 Analysis

Should You Buy Genpact Ltd (G) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

40.390

1 Day change

7.14%

52 Week Range

56.760

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is breaking below near-term support with bearish momentum (MACD histogram negative and expanding) into earnings.
Despite extremely oversold RSI (potential for a snap-back), the setup favors waiting for either (1) a post-earnings reaction or (2) a reclaim of ~$39.5 support before buying.
Options are pricing a big move (IV very high), which makes the pre-earnings entry less attractive for an impatient buyer.
Intellectia signals do NOT provide a strong override today (no AI Stock Picker or SwingMax entry).

Technical Analysis

Trend/Momentum: Bearish near term — MACD histogram -0.798 and getting worse (downtrend pressure still increasing).
RSI: RSI(6) at ~6.38 = extremely oversold; this often precedes a short-term bounce, but it’s not a confirmed reversal by itself.
Moving averages: Converging MAs suggests a transition zone, but current momentum is still down.
Key levels: Current ~$38.34 is below S1 ~$39.52 (lost support). Next support S2 ~$37.56. Resistance/pivot overhead: pivot ~$42.69, then ~$45.85.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open Interest Put/Call ~1.0 (balanced), but volume Put/Call ~0.35 shows calls dominating today’s flow (short-term bullish trading activity).
Volatility: 30D IV ~57.3 vs historical vol ~40.7; IV percentile ~97.6 = options are very expensive and implying an outsized move.
Activity: Today’s volume ~162 and ~186% of 30D average; open interest ~108% of average → elevated event-driven positioning.
Event context: Earnings after-hours 2026-02-05 increases gap-risk; options market is clearly bracing for a move.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst imminent (2026-02-05 after hours); a beat/raise could trigger a sharp rebound given the oversold condition.
- Recent quarter showed solid growth and margin improvement (supports a bullish fundamental narrative if confirmed again).
- Call-heavy option volume today suggests some traders are positioning for upside into the event.

Neutral/Negative Catalysts

- Price action is weak: broke below ~$39.5 support and MACD is still deteriorating, suggesting sellers remain in control.
- Hedge funds are net selling (selling amount up ~805.73% QoQ) — a notable sentiment headwind.
- Options IV is extremely elevated (IV percentile ~97.6), meaning “good news” may already be partially priced and post-earnings whipsaw is more likely.
- No supportive news flow in the last week to counter the downtrend.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $1.291B, +6.63% YoY (steady top-line growth).
Net income: $145.8M, +9.80% YoY (profit growth outpacing revenue).
EPS: $0.83, +12.16% YoY (solid earnings leverage).
Gross margin: 35.73%, +1.82% YoY (margin expansion is a positive trend).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst tone is mixed-to-constructive (more “neutral/market perform” than outright bearish).
2025-12-12: Susquehanna initiated at Neutral with $50 PT.
2025-11-07: BMO reiterated Market Perform, PT trimmed to $48 (still well above current price).
Wall St pros: improving margins, steady growth, and upside to targets if execution continues.
Wall St cons: ratings are not strongly bullish overall, and the stock’s current tape is contradicting the higher price targets.
Influential/political trading: No recent congress trading data available; insiders neutral (no significant recent trend).

8 Analyst Rating

Wall Street analysts forecast G stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for G is 50.57 USD with a low forecast of 43 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

5 Hold

0 Sell

Moderate Buy

Current: 37.700

Low

Averages

50.57

High

Current: 37.700

Low

Averages

50.57

High

Needham

Mayank Tandon

Buy

downgrade

$53 -> $50

AI Analysis

2026-02-06

New

Reason

Needham

Mayank Tandon

Price Target

$53 -> $50

AI Analysis

2026-02-06

New

downgrade

Buy

Reason

Needham analyst Mayank Tandon lowered the firm's price target on Genpact to $50 from $53 and keeps a Buy rating on the shares. The company posted solid Q4 results, beating estimates on the top and bottom line, driven primarily by its Advanced Technology Solutions segment, the analyst tells investors in a research note.

Susquehanna

Neutral

downgrade

$50 -> $42

2026-02-06

New

Reason

Susquehanna

Price Target

$50 -> $42

2026-02-06

New

downgrade

Neutral

Reason

Susquehanna lowered the firm's price target on Genpact to $42 from $50 and keeps a Neutral rating on the shares. The firm said solid Execution, ATS Momentum Continues, Core Questions Remain. Genpact delivered a solid 4Q25, with results modestly ahead of expectations and continued momentum in Advanced Technology Solutions (ATS) offsetting slower growth in the core business.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for G

Unlock Now

G Should I Buy

G Should I Buy

Should You Buy Genpact Ltd (G) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch